Eli Lilly’s supposed weight loss drug helped people lose an average of 56 poundsforbes
Eli Lilly preparing rettrutide application after positive weight loss dataWSJ
Lilly’s triple agonist, rettrutide, was successful in two additional Phase 3 obesity trials, producing significant improvements in weight and A1CEli Lilly and Company
Eli Lilly says it will apply for approval of next-generation obesity drug in 2027 as it approves two more trialscnbc
Eli Lilly’s next-generation weight loss shot clears another hurdlebloomberg.com
